The INCY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the INCY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The INCY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View INCY Detailed Price Forecast - CNN Money||View INCY Detailed Summary - Google Finance|
|View INCY Detailed Summary - Yahoo! Finance||View INCY Stock Research & Analysis - Zacks.com|
|View INCY Trends & Analysis - Trade-Ideas||View INCY Major Holders - Barrons|
|View INCY Call Transcripts - NASDAQ||View INCY Breaking News & Analysis - Seeking Alpha|
|View INCY Annual Report - CompanySpotlight.com||View INCY OTC Short Report - OTCShortReport.com|
|View INCY Fundamentals - TradeKing||View INCY SEC Filings - Bar Chart|
|View Historical Prices for INCY - The WSJ||View Performance/Total Return for INCY - Morningstar|
|View the Analyst Estimates for INCY - MarketWatch||View the Earnings History for INCY - CNBC|
|View the INCY Earnings - StockMarketWatch||View INCY Buy or Sell Recommendations - MacroAxis|
|View the INCY Bullish Patterns - American Bulls||View INCY Short Pain Metrics - ShortPainBot.com|
|View INCY Stock Mentions - StockTwits||View INCY Stock Mentions - PennyStockTweets|
|View INCY Stock Mentions - Twitter||View INCY Investment Forum News - Investor Hub|
|View INCY Stock Mentions - Yahoo! Message Board||View INCY Stock Mentions - Seeking Alpha|
|View Insider Transactions for INCY - SECform4.com||View Insider Transactions for INCY - Insider Cow|
|View INCY Major Holdings Summary - CNBC||View Insider Disclosure for INCY - OTC Markets|
|View Insider Transactions for INCY - Yahoo! Finance||View Institutional Holdings for INCY - NASDAQ|
|View INCY Stock Insight & Charts - FinViz.com||View INCY Investment Charts - StockCharts.com|
|View INCY Stock Overview & Charts - BarChart||View INCY User Generated Charts - Trading View|
Incyte (INCY) Announces Positive Results on Jakafi for GVHD
Posted on Friday June 22, 2018
Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.
Incyte to Present Diversified Development Portfolio and Opportunities for Accelerated Growth at 2018 Investor and Analyst Event
Posted on Thursday June 21, 2018
Incyte Corporation (INCY) will host an investor and analyst event in New York City today to provide a comprehensive update on the Company’s growth opportunities and late-stage development portfolio. “The presentations today are intended to highlight our diversified development portfolio and its potential to accelerate our top-line growth in the near term,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “The success of the REACH1 study of Jakafi in steroid-refractory acute graft-versus-host disease (GVHD) announced earlier today is excellent news for patients, and also further reinforces the potential of JAK inhibition in GVHD and our development strategy to address this devastating disease.
Incyte Corporation (INCY) today announced positive topline results from its ongoing pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi®) in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease (GVHD). The study met its primary endpoint, demonstrating an overall response rate (ORR) of 55 percent (n=39/71) at Day 28. In addition, the best overall response rate (BORR), the number of patients achieving a response at any time point during the study, was 73 percent (n=52/71).
Former Incyte CEO Buys Slumping Nektar Shares
Posted on Monday June 11, 2018
Roy A. Whitfield, Nektar Therapeutics (NKTR) director, and former chairman and chief executive of Incyte (INCY), bought $290,200 in Nektar shares last week, buying as the biotech's shares show weakness. ...